COFEPRIS Guide
COFEPRIS regulatory translation requirements.
A technical guide to the linguistic, certification, and formatting rules Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios applies to clinical trial translation for drug and device submissions — and why general-purpose AI translation creates avoidable requerimientos in first-cycle review.
Published July 2026
The context
Mexico reviews in Spanish, and reviews it carefully.
COFEPRIS is the federal regulator for medicines, medical devices, biologics, and clinical research in Mexico. Every clinical trial authorization (CTA), protocol amendment, and sanitary registration dossier is reviewed in Spanish. Source documents in English or another language are accepted only with a translation that meets Mexico's formal requirements. Anything less generates an oficio or requerimiento, and each clarification resets the review clock.
For U.S. and European sponsors, this is easy to underestimate. Mexico's Spanish is not interchangeable with other regional variants, and COFEPRIS has specific expectations for how medical terms, statistical language, and legal attestations are rendered. A translation that is fluent but not regulator-ready is the most common source of first-cycle delay.
What must be translated
The documents that move a Mexico submission.
For a clinical trial authorization, COFEPRIS expects Spanish translations of the protocol, informed consent form, investigator's brochure, case report forms, and serious adverse event / SUSAR narratives. Device trials add instructions for use, risk analysis, and biocompatibility summaries. For marketing authorization, the list expands to include labeling, CMC sections, stability data, and certificate attestations.
Each document must be complete. Partial translations, translated body text with untranslated appendices, or omitted footnotes are treated as incomplete submissions. COFEPRIS reviewers compare the Spanish translation against the source document line by line in disputed areas, so the two versions must match exactly in structure and numbering.
Certification
COFEPRIS expects more than a bilingual page.
Mexican regulatory submissions typically require translations to be certified by a perito tradutor — a certified translator recognized under Mexican law — or a Mexican public translator. The certification must include the translator's full name, credentials, signature, and date, and usually a statement that the translation is accurate and complete to the best of the translator's knowledge.
Legal instruments such as powers of attorney, apostilles, and corporate resolutions may also need notarization. The exact requirement depends on the local delegate office and the type of submission, so sponsors should confirm the current checklist before filing. The safest default is to prepare a certified translation for every clinical and regulatory document, and notarization for any document that will be used as a legal instrument.
Where translations fail
The four most common sources of COFEPRIS queries.
- Terminology mismatches. General-purpose translation engines often map English clinical terms to Peninsular or South American Spanish. COFEPRIS expects Mexican usage, and reviewers will flag deviations even when they are technically understandable elsewhere.
- Literal back-translations. A protocol that has been translated literally back into English for the sponsor can drift from the source. COFEPRIS may ask for a corrected Spanish version that aligns with the original protocol.
- Missing certificates or signatures. Translations submitted without the translator's credentials, or with cut-off signatures or dates, are rejected. This is a paperwork failure, not a linguistic one, but it costs the same amount of time.
- Inconsistent drug or device nomenclature. If a product is referred to by three different names across the protocol, informed consent, and IFU, COFEPRIS will ask for a harmonized version. Controlled vocabulary is not optional.
How we cover this
The First-Pass Acceptance Program for Mexico.
Our clinical trial translation service pairs AI-assisted translation with medical review by clinicians who understand Mexican regulatory Spanish, then routes legal instruments to certified Mexican translators before the dossier is assembled. The output is a Spanish submission package aligned to COFEPRIS's expectations — not a generic translation.
We back it with a written SLA: zero critical errors on delivery, or we re-issue at no cost and credit $2,500 per business day of delay. For COFEPRIS submissions, that credit is priced against the actual cost of a delayed protocol authorization or a late registration.
What "specialized" actually means
Clinical trial translation services are a regulatory discipline, not a language service.
A specialized workflow pairs AI-assisted translation with medical review by clinicians who read the local regulatory guidance for a living. The AI compresses time. The medical reviewer preserves clinical and regulatory intent. Neither one alone is a substitute for the other, and the Mexico-market outcome depends on both being present.
For a deeper look at where general-purpose AI translation falls short in Phase III documentation, read our comparison of AI vs. medical review accuracy.
Related resources
Continue reading across the LatAm regulatory stack.
Clinical Trial Translation Services hub
The Amavita overview of LatAm regulator coverage, MD-led review, and the First-Pass Acceptance SLA.
Read more →ANVISA translation requirements (Brazil)
Portuguese submission rules, tradutor público juramentado requirements, and common exigências.
Read more →INVIMA translation requirements (Colombia)
Colombian Spanish submission rules, certified translator requirements, and common auto de requerimiento.
Read more →ANMAT translation requirements (Argentina)
Disposición 6677/10, traductor público matriculado, and rioplatense Spanish for the informed consent.
Read more →LatAm market access impact
How translation quality shapes the speed of market clearance and audit success across Latin America.
Read more →AI vs. medical review accuracy
Where general-purpose AI translation fails on Phase III documentation and how MD-led review closes the gap.
Read more →Ready to move a Mexico program? Start a COFEPRIS pilot with Amavita →
Next step
Move a Mexico program through the workflow.
Tell us about a COFEPRIS submission or Mexico clinical trial on your calendar. Our team will reach out within 2 business days with a scoped pilot proposal.